EP4 Receptor Antagonists

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Format: Word Table
Product Line: Target Pipeline List
Product Code: LMTPL033
Release Date: January of 2019
Loading...

EP4 Receptor Antagonists – Target Pipeline List

Target: Prostaglandin E2 (PGE2) type EP4 receptor

This Target Pipeline list provides an overview of small molecules targeting the EP4 receptor of PGE2 in the tumor microenvironment in preclinical or clinical development for treatment of solid tumors.

Prostaglandin E2 (PGE2) has been shown to contribute to an immunosuppressive environment in cancer by enhancing the activity of regulatory immune cells and suppressing the activity of effector immune cells. EP4 is a high-affinity receptor of PGE2 and is known to facilitate these immunosuppressive activities.

It is known that activating EP4 receptors causes monocytes to differentiate into M2 macrophages which have immuno-suppressive effects. As demonstrated in preclinical studies, inhibiting EP4 receptors reduces M2 macrophages, and by increasing M1 macrophages which activate immune response, antitumor effects can be expected.

In preclinical studies, inhibition of EP4 has been shown to boost the immune response through modulation of multiple immune cell types, and in combination with checkpoint inhibitors has yielded significant reduction in tumor growth relative to either agent alone.

La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.

The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.

Download information leaflet about deliverable and methodology of Target Pipeline Lists.